All In Biotech

Drug Trial Radar · NCT05423691

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 27, 2022

Primary completion

Apr 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Cellenkos, Inc.Industry
Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Conditions

  • Myelofibrosis

Interventions

  • CK0804Drug

    CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine Treatment limiting toxicity (TLT) as defined belowTime frame: 28 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis Health

    Sacramento, California · Recruiting

  • Columbia University

    New York, New York · Not yet recruiting

  • Montefiore Einstein Cancer Center

    The Bronx, New York · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.